Skip to content
Search

Latest Stories

Cannabis in children's candy: Haribo recalls sweets

Forensic testing later revealed the presence of cannabis.

Haribo's Sweet Shock: Cannabis Contamination Triggers Recall

Consumers in the Netherlands are being urged to check any 1kg packs of Haribo Happy Cola F!ZZ sweets

iStock

Haribo has recalled a batch of its Happy Cola F!ZZ sweets in the Netherlands after traces of cannabis were discovered in several packs. The recall was prompted after multiple individuals, including children, reported feeling unwell after consuming the sweets.

According to the Netherlands Food and Consumer Product Safety Authority (NVWA), three 1kg packs were linked to complaints of dizziness and other health-related symptoms. The NVWA confirmed that the affected sweets were genuine Haribo products and said the recall was being carried out as a precautionary measure.


A spokesperson for the NVWA told Dutch news agency ANP that it was still unclear how the cannabis ended up in the sweets. “The police are investigating the matter further,” the spokesperson said.

Dutch police confirmed that a couple from the Twente region brought in a packet of the cola-bottle-shaped sweets after their children became ill upon eating them. Forensic testing later revealed the presence of cannabis.

Police spokesperson Chantal Westerhoff said, “We want to know exactly how it got into the candy and, of course, how the bags ended up in the store.”

Haribo stated that the recall only affects 1kg bags of the Happy Cola F!ZZ sweets with a specific product code and a use-by date of January 2026. Consumers who purchased the affected products are eligible for a full refund.

Patrick Tax, vice-president of marketing at Haribo, said the issue was limited to a small number of cases in the eastern part of the Netherlands. “The safety of our consumers is our highest priority and Haribo takes this incident very seriously,” he said.

Tax added that Haribo is cooperating closely with the Dutch authorities to assist in the ongoing investigation. “This is a live issue and we are working closely with the Dutch authorities to support their investigation and establish the facts,” he told Agence France-Presse.

The NVWA has issued a clear warning to consumers not to eat the sweets from the affected batch.

In a separate case in 2023, six children aged between four and 14 became unwell in The Hague after consuming sweets that contained THC, one of the active substances in cannabis. However, the products involved in that incident were not regular commercial items.

Authorities have noted a rise in cases where drug smugglers disguise cannabis-laced products as common confectionery, including popular brands. There have also been reports of imitation sweets resembling Haribo products being sold online with added THC.

The investigation into how cannabis was introduced into the recalled Haribo sweets is ongoing. Police and food safety officials continue to examine supply chain links and retail distribution to identify the source of contamination.

For now, consumers in the Netherlands are being urged to check any 1kg packs of Haribo Happy Cola F!ZZ sweets they may have purchased and return them if they match the affected batch.

More For You

Weight Loss Drug

Health officials expect the rollout to benefit around 220,000 adults over the next 3 years

iStock

NHS GPs to prescribe Mounjaro in nationwide obesity treatment plan

Key points

  • NHS GPs in England can now prescribe Mounjaro (tirzepatide) for weight loss
  • The programme aims to support 220,000 people over three years
  • Eligible patients must have a BMI over 40 and at least four obesity-related health issues
  • GP leaders raise concerns over increased workload
  • Pharmacists urge a broader weight management approach

NHS expands obesity treatment with Mounjaro

The NHS in England is set to begin prescribing Mounjaro, a weight loss injection, through GP surgeries starting Monday. The move marks the first time family doctors will be authorised to directly prescribe the anti-obesity drug tirzepatide as part of a wider national health initiative.

Health officials expect the rollout to benefit around 220,000 adults over the next three years. The drug will be made available to those with a body mass index (BMI) above 40 who also suffer from at least four other obesity-related conditions, such as type 2 diabetes, high blood pressure, or sleep apnoea.

Keep ReadingShow less
UK heatwave deaths

Around 85% of the projected deaths are likely to involve people over the age of 65

iStock

Scientists warn current UK heatwave may cause nearly 600 early deaths

Almost 600 premature deaths are expected to occur during the ongoing heatwave affecting England and Wales, according to a new rapid analysis by leading scientists. The majority of fatalities are projected among older adults, with London and the West Midlands likely to be the worst-affected areas.

Climate change driving deadly temperatures

Researchers say the extreme temperatures, which have reached 32°C in parts of south-east England, would have been nearly impossible without the influence of human-caused climate change. Pollution from burning fossil fuels has raised the likelihood of such heatwaves by around 100 times, experts say.

Keep ReadingShow less
Amycretin

'The Lancet' and presentations at the American Diabetes Association’s 2025

iStock

New weight-loss pill Amycretin shows greater impact than jabs, study finds

A new weight-loss drug, amycretin, has delivered the most significant results yet for appetite-suppressing GLP-1 medications, according to two newly published studies in The Lancet and presentations at the American Diabetes Association’s 2025 Scientific Sessions in Chicago.

Record weight loss from Amycretin injections

Researchers found that participants receiving high-dose weekly injections of amycretin lost 24.3 per cent of their body weight over 36 weeks. This outcome surpasses the results seen in longer trials involving other GLP-1 drugs such as tirzepatide (sold as Mounjaro), which previously led the field with an average weight loss of 20 per cent over 72 weeks.

Keep ReadingShow less
Hulk Hogan

Hogan’s current hospital stay follows a neck fusion surgery he underwent in May 2025

Getty Images

Hulk Hogan hospitalised for back and neck issues, rep confirms he is not on deathbed

WWE Hall of Famer Hulk Hogan has been hospitalised for ongoing neck and back issues, but representatives have confirmed he is not in critical condition, dismissing online speculation suggesting otherwise.

The 71-year-old wrestling icon, whose real name is Terry Bollea, was reported by TMZ Sports to be undergoing treatment related to injuries sustained during his decades-long in-ring career. His representative said Hogan is already mobile again and “not on his deathbed”, following false claims made on air by Florida radio personality Bubba the Love Sponge.

Keep ReadingShow less
UK heatwave health risks

Several hidden threats linked to heat waves often go unnoticed

iStock

7 hidden heatwave health risks you may overlook

As temperatures across the UK continue to rise, so too do the health risks associated with extreme heat. While sunburn and dehydration are well-known dangers, several hidden threats linked to heat waves often go unnoticed. With climate change intensifying the frequency and severity of hot spells, some forecasts suggesting 40 °C days could become a regular feature in the next 12 years, it’s essential to understand these lesser-known risks and how to protect yourself.

1. Skin reactions triggered by common medications

Certain widely-used medications can increase sensitivity to sunlight, making people more prone to rashes, blistering, and sunburn—even on cloudy days. This includes nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, some antibiotics such as doxycycline, statins, antidepressants, and hormone replacement therapy (HRT).

Keep ReadingShow less